Alazar N Ghebremeskel

This inventor holds 16 USPTO granted patents and 21 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in Ocular Drug Delivery. Top assignee: Allergan, Inc.. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alazar N Ghebremeskel. Retrieved from https://idiyas.com/inventor/alazar-n-ghebremeskel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 21)

% Patents Active = 87.5

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 20)

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 96(Granted Patents)

Company Filing History:

16 out of 2,287

Allergan, Inc.

patents

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Intraocular Implants

Biodegradable Implants

Prostaglandin Delivery

Sustained Release

Therapeutic Agents

Prostamide Systems

Alpha-2 Agonist

Drug Delivery Systems

Polymeric Implants

Therapeutic Uses

Intracameral Implants

Latanoprost Implant

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12004995 - Intraocular implant with high loading of a prostamide (2024-06-11),

2. 10842739 - Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof (2020-11-24),

3. 10471004 - Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof (2019-11-12),

4. 10463772 - Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof (2019-11-05),

5. 10278919 - Intracameral sustained release therapeutic agent implants (2019-05-07),

6. 9980974 - Prostamide-containing intraocular implants and methods of use thereof (2018-05-29),

7. 9861576 - Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof (2018-01-09),

8. 9522113 - Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof (2016-12-20),

9. 9504696 - Intracameral sustained release therapeutic agent implants (2016-11-29),

10. 9492316 - Prostamide-containing intraocular implants and methods of use thereof (2016-11-15),

11. 9161929 - Solvent cast film sustained release latanoprost implant (2015-10-20),

12. 9095506 - Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof (2015-08-04),

13. 9061065 - Intracameral sustained release therapeutic agent implants (2015-06-23),

14. 8771745 - Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof (2014-07-08),

15. 8715713 - Solvent cast film sustained release latanoprost implant (2014-05-06),

Title: Alazar N Ghebremeskel: Innovator in Ocular Implants

Introduction

Alazar N Ghebremeskel is a prominent inventor based in Irvine, CA, known for his significant contributions to the field of ocular implants. With a total of 16 patents to his name, he has made remarkable advancements in the treatment of glaucoma and other ocular conditions.

Latest Patents

His latest patents include an intraocular implant designed for high loading of a prostamide. This biodegradable intraocular implant aims for the immediate and sustained reduction of intraocular pressure, providing a treatment option for glaucoma patients. Another notable patent involves biodegradable alpha-2 agonist polymeric implants. These biocompatible implants incorporate an alpha-2 adrenergic receptor agonist and a polymer to facilitate the extended release of the agonist into the eye, addressing various ocular conditions, including elevated intraocular pressure.

Career Highlights

Alazar is currently associated with Allergan, Inc., where he continues to innovate in the field of ocular health. His work has been instrumental in developing new therapeutic options for patients suffering from glaucoma and other related conditions.

Collaborations

He has collaborated with notable colleagues, including Michael R Robinson and Lon T Spada, contributing to the advancement of ocular implant technologies.

Conclusion

Alazar N Ghebremeskel's innovative work in ocular implants has significantly impacted the treatment of glaucoma and other ocular conditions. His dedication to research and development continues to pave the way for future advancements in this critical field.

Profile summary based on public USPTO records.